Lyla Lindsey
The HPV vaccine has been a significant development in the field of medicine, offering protection against the human papillomavirus, which causes cervical cancer and genital warts. Australia has played a pivotal role in the story of the HPV vaccine, with University of Queensland researcher Professor Ian Frazer initiating vaccine development in the 1990s. This led to the creation of Gardasil®, which was approved by the Australian Therapeutic Goods Administration in 2006, and subsequently included in Australia's National Immunisation Program in 2007, making it the first country to do so. The vaccine has since been distributed in over 130 countries, significantly reducing the risk of HPV-related cancers worldwide.
| Characteristics | Values |
|---|---|
| Country that developed the HPV vaccine | Australia |
| Researchers | Professor Ian Frazer and Dr Jian Zhou |
| University | University of Queensland |
| Year of development | 1990s |
| Year of approval | 2006 |
| Vaccine name | Gardasil |
| Year Australia included HPV vaccine in its National Immunisation Program | 2007 |
| Age group | Girls aged 12 to 13 years |
| Catch-up programs | Girls aged 14 to 18 and young women between 18 and 26 years |
| Year of inclusion of boys in the program | 2013 |
| Age group for boys | 12-13 years |
| Reduction in HPV types covered by the vaccine in 18-24-year-old women | 77% |
| Reduction in precancerous abnormalities in 20-24-year-olds | 34% |
| Reduction in cervical cancer incidence | 24-36% |
| Reduction in cervical cancer mortality | 29-36% |
| Expected reduction in cervical cancer diagnosis and death in Australia with the new HPV vaccine | 54% |
Explore related products
What You'll Learn
HPV vaccine development in Australia
The development of the HPV vaccine in Australia is a success story in cervical cancer prevention. In Australia, cancers of the cervix and uterus were once the leading causes of cancer-related deaths in women. HPV, or human papillomavirus, is a viral infection that is sexually transmitted and can cause cancers and genital warts.
In the 1990s, University of Queensland researcher and 2006 Australian of the Year, Professor Ian Frazer, began developing a vaccine for HPV along with his colleague, Dr Jian Zhou. In 1991, Frazer's team filed the initial patent for the immunogenic VLP technology that could be used to create an HPV vaccine. Research on this technology continued at the University of Queensland until 1994 when UniQuest licensed the intellectual property to CSL Limited, an Australian biotechnology company. CSL funded further research and development of an HPV vaccine, and in 1996, they sublicensed the technology to Merck & Co., Inc., an American multinational pharmaceutical company. Merck conducted several clinical trials in over 13 countries, including Phase 3 studies involving more than 12,000 women between the ages of 15 and 26.
In 2006, the Australian Therapeutic Goods Administration approved Gardasil, the MSD/Merck & Co., Inc. vaccine, which provided protection against four HPV strains known to cause almost all cases of genital warts and a high number of cervical cancer cases. By 2007, Australia became the first country to include the HPV vaccine in its National Immunisation Program for girls aged 12 to 13, with catch-up programs introduced for girls and young women up to age 26 from 2009. In 2013, the Australian government extended the vaccination program to include boys, making it one of 22 countries with a gender-neutral HPV vaccination program.
The HPV vaccine has significantly lowered the risk of HPV-related cancers for thousands of women worldwide. In the first four to five years of the program, there was a 77% decrease in the number of 18-24-year-old women with HPV, and precancerous abnormalities also decreased by 34% in 20-24-year-olds. The vaccine has also led to a marked decline in anogenital warts in women in their early 20s and a decline in the rates of genital warts in young heterosexual men.
Australia continues to make advancements in HPV vaccine development, with a new vaccine expected to be reviewed for inclusion in the National Immunisation Program Schedule. The switch to HPV-based screening and the potential introduction of a next-generation vaccine are expected to further enhance cervical cancer prevention in the country.
Australian Government's Response to the Great Depression
You may want to see also
Explore related products
HPV vaccine rollout
The HPV vaccine, Gardasil®, was first approved by the Therapeutic Goods Administration in Australia in 2006. The vaccine was developed by University of Queensland researcher and Australian of the Year (2006), Professor Ian Frazer, and his colleague, Dr Jian Zhou. Frazer's team first filed the patent for the immunogenic VLP technology that could be used to create an HPV vaccine in 1991.
In 2007, Australia became the first country in the world to implement a national HPV vaccination program. The program initially targeted girls in Year 7, aged 12 to 13. Catch-up programs for girls aged 14 to 18 and young women between 18 and 26 were introduced in 2009.
In 2013, the Australian government extended the HPV vaccination program to include boys, making it one of 22 countries and territories with a gender-neutral HPV vaccination program. This decision was driven by the substantial disease burden in men, particularly MSM (men who have sex with men), who would not benefit from a female-only vaccination program, and the expected incremental reduction in HPV infections among women.
The HPV vaccination program in Australia has been highly successful. In the first four to five years of the program, there was a 77% decrease in the number of 18 to 24-year-old women with HPV types covered by the vaccine. Precancerous abnormalities decreased by 34% in 20 to 24-year-olds, lowering their lifetime risk of developing cervical cancer. The vaccine has also led to a marked decline in anogenital warts in women in their early 20s and a decline in genital warts in young heterosexual men.
Australia continues to make advancements in HPV vaccination and cervical cancer prevention. In 2017, the National Cervical Screening Program was renewed, replacing Pap smear testing with HPV DNA-based testing. This change is expected to further reduce cervical cancer incidence and mortality rates.
A new HPV vaccine has also been approved for use in the USA and Europe and is expected to be reviewed for inclusion in Australia's National Immunisation Program Schedule in the coming years. This next-generation vaccine is predicted to further reduce cervical cancer diagnoses and deaths in Australia.
Australian Citizenship: Steps to Apply and Acquire
You may want to see also
Explore related products
HPV vaccine impact
The HPV vaccine has had a significant impact on public health, particularly in the prevention of cervical cancer and other HPV-related cancers. HPV, or human papillomavirus, is the cause of nearly all cervical cancers.
In Australia, the development and rollout of the HPV vaccine is considered a major success story. The University of Queensland researcher and 2006 Australian of the Year, Professor Ian Frazer, first started developing a vaccine for HPV in the 1990s, along with his colleague, Dr Jian Zhou. In 1991, Frazer's team filed the initial patent for the immunogenic VLP technology that could be used to create an HPV vaccine. This technology was licensed to CSL Limited, an Australian biotechnology company, which funded further research and development. The vaccine, Gardasil®, was approved by the Therapeutic Goods Administration in 2006 and provided protection against four HPV strains that cause genital warts and cervical cancer.
In 2007, Australia became the first country to include the HPV vaccine in its National Immunisation Program, initially offering it to girls aged 12 to 13, with catch-up programs for older girls and young women introduced later. In 2013, the program was expanded to include boys, making Australia one of the first countries to implement a gender-neutral HPV vaccination program. This was considered vital for equity reasons and to ensure the acceptability of the program.
The impact of the HPV vaccine in Australia has been significant. In the first four to five years of the program, there was a 77% decrease in the number of 18-24-year-old women with HPV types covered by the vaccine. Precancerous abnormalities also decreased by 34% in this age group, lowering their lifetime risk of developing cervical cancer. There was also a notable decline in anogenital warts in young women and a decline in genital warts in heterosexual men, even before they were included in the vaccination program.
The HPV vaccine has also had a substantial impact globally. Over 200 million doses have been distributed in 130 countries, significantly lowering the risk of HPV-related cancers for thousands of women. A study in Sweden involving 1.7 million women found that the vaccine reduced cervical cancer incidence by nearly 90% in those vaccinated before the age of 17. Similarly, a UK study showed that the HPV vaccine reduced cervical cancer rates by almost 90% in women in their 20s who received the vaccine at ages 12 to 13.
The widespread use of the HPV vaccine, in combination with cervical cancer screening, has the potential to drastically reduce cervical cancer rates and save lives. A new HPV vaccine is also on the horizon, which is expected to further enhance the impact of HPV vaccination programs.
Converting Euros to Australian Dollars: How Much Is It?
You may want to see also
Explore related products
HPV vaccine safety
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. HPV infections can persist and progress to six different kinds of cancer in women and men later in life: cervical, anal, oropharyngeal (back of the throat), penile, vaginal, and vulvar. HPV vaccines, such as Gardasil 9, have been developed to protect against these cancers.
The HPV vaccine has been proven safe and effective for over 15 years, with more than 135 million doses distributed worldwide. The vaccine was first approved by the Food and Drug Administration (FDA) in 2006, and since then, data has continued to show its safety and efficacy. The CDC and FDA closely monitor the safety of HPV vaccines, and any detected safety concerns are reported to health officials, healthcare professionals, and the public.
In Australia, researchers at the University of Queensland played a crucial role in developing the technology behind the world's first HPV vaccines. In 1991, Professor Ian Frazer's team filed the initial patent for the immunogenic VLP technology that could be used to create an HPV vaccine. After further research and development, the vaccine was approved by the Australian Therapeutic Goods Administration in 2006, and Australia became the first country to include the HPV vaccine in its National Immunisation Program in 2007, initially for girls aged 12 to 13. The program was later expanded to include teenage boys in 2013, making Australia one of the first countries to implement a gender-neutral HPV vaccination program.
While the HPV vaccine is generally safe, it can have side effects like any other medicine. However, many people who receive the vaccine experience no side effects at all. The most common side effects are typically mild, such as a sore arm from the injection site. Severe allergic reactions are rare but can be life-threatening and include symptoms such as hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, and weakness.
Despite the strong evidence of its safety and effectiveness, there has been an increase in parental concerns about the HPV vaccine in recent years, leading to a decline in vaccination rates. During the same period, reports of serious health issues after HPV vaccination remained rare. This discrepancy highlights the importance of addressing parents' concerns and providing accurate information about vaccine safety.
Toluene's Legality in Australia: What's the Verdict?
You may want to see also
Explore related products
HPV vaccine research
The HPV vaccine, Gardasil, was first developed in Australia by University of Queensland researcher and 2006 Australian of the Year Professor Ian Frazer and his colleague, the late Dr Jian Zhou. Frazer's team filed the initial patent for the immunogenic VLP technology that could be used to develop an HPV vaccine in 1991. Research on this technology continued at the University of Queensland until 1994, when it was licensed to an Australian biotechnology company, CSL Limited, which funded further research and development. In 1996, CSL sub-licensed the technology to American multinational pharmaceutical company Merck & Co., Inc., which conducted several clinical trials in over 13 countries.
The HPV vaccine was approved by the Therapeutic Goods Administration in 2006 and was included in Australia's National Immunisation Program in 2007, initially for girls only. In 2013, the program was expanded to include boys, making Australia one of 22 countries and territories with a gender-neutral HPV vaccination program. The recommended schedule for adolescents and young adults aged 9-25 years is one dose, while for those aged 26 years and above, three doses are recommended.
The HPV vaccine has been highly effective in preventing HPV infections and reducing the risk of HPV-related cancers. In the first four to five years of the program, there was a 77% decrease in the number of 18-24-year-old women with HPV, and precancerous abnormalities decreased by 34% in 20-24-year-olds. The vaccine has also led to a marked decline in anogenital warts in women and a decline in the rates of genital warts in young heterosexual men.
Australia continues to make advancements in HPV vaccine research and development. A new HPV vaccine has been approved for use in the USA and Europe and is expected to be reviewed for inclusion in Australia's National Immunisation Program. Research predicts that this next-generation vaccine will further reduce cervical cancer diagnoses and deaths in Australia.
Understanding VAT Rates on Australian Imports
You may want to see also
Frequently asked questions
Yes, the HPV vaccine was developed in Australia by University of Queensland researcher and Australian of the Year (2006) Professor Ian Frazer and his colleague, the late Dr Jian Zhou.
The initial patent for the immunogenic VLP technology that could be used to develop an HPV vaccine was filed in 1991. Research on this technology continued at the University of Queensland until 1994, when it was licensed to an Australian biotechnology company for further development.
The HPV vaccine was approved by the Australian Therapeutic Goods Administration in 2006. In 2007, Australia became the first country in the world to include the HPV vaccine in its National Immunisation Program for girls aged 12 to 13 years.
The HPV vaccine has been highly effective in Australia. In the first four to five years of the program, there was a 77% decrease in the number of 18-24-year-old women with HPV. Precancerous abnormalities also decreased by 34% in 20-24-year-olds. Cervical cancer prevention in Australia is expected to become even more effective with the switch to HPV-based screening and the introduction of a next-generation vaccine.
